Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.

Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W.

PLoS Med. 2007 Oct 9;4(10):e294.

2.

Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.

Takeuchi S, Yano S.

Respir Investig. 2014 Nov;52(6):348-56. doi: 10.1016/j.resinv.2014.10.002. Epub 2014 Oct 31. Review.

PMID:
25453378
3.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
4.

EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.

Takeuchi K, Ito F.

FEBS J. 2010 Jan;277(2):316-26. doi: 10.1111/j.1742-4658.2009.07450.x. Epub 2009 Nov 18. Review.

5.

Epidermal growth factor receptor mutations in lung adenocarcinoma.

Siegelin MD, Borczuk AC.

Lab Invest. 2014 Feb;94(2):129-37. doi: 10.1038/labinvest.2013.147. Epub 2013 Dec 30. Review.

6.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors.

Huang L, Fu L.

Acta Pharm Sin B. 2015 Sep;5(5):390-401. doi: 10.1016/j.apsb.2015.07.001. Epub 2015 Jul 26. Review.

7.

Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.

Petitprez A, Larsen AK.

Curr Pharm Des. 2013;19(5):958-64. Review.

PMID:
22973964
8.

Predicting resistance by selection of signaling pathways.

Karachaliou N, Rosell R, Molina MA, Viteri S.

Transl Lung Cancer Res. 2014 Apr;3(2):107-15. doi: 10.3978/j.issn.2218-6751.2014.02.04. Review.

9.

Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

Han W, Lo HW.

Cancer Lett. 2012 May 28;318(2):124-34. doi: 10.1016/j.canlet.2012.01.011. Epub 2012 Jan 17. Review.

10.

AKT inactivation causes persistent drug tolerance to EGFR inhibitors.

Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F.

Pharmacol Res. 2015 Dec;102:132-7. doi: 10.1016/j.phrs.2015.09.022. Epub 2015 Oct 22. Review.

PMID:
26453958
11.

Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.

Freemantle SJ, Dmitrovsky E.

Cancer Prev Res (Phila). 2010 Dec;3(12):1513-8. doi: 10.1158/1940-6207.CAPR-10-0297. Review.

12.

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation.

Becker K, Xu Y.

World J Clin Oncol. 2014 Oct 10;5(4):560-7. doi: 10.5306/wjco.v5.i4.560. Review.

13.

Sugar-free approaches to cancer cell killing.

El Mjiyad N, Caro-Maldonado A, Ramírez-Peinado S, Muñoz-Pinedo C.

Oncogene. 2011 Jan 20;30(3):253-64. doi: 10.1038/onc.2010.466. Epub 2010 Oct 25. Review.

PMID:
20972457
14.

Understanding the mechanisms of drug-associated interstitial lung disease.

Higenbottam T, Kuwano K, Nemery B, Fujita Y.

Br J Cancer. 2004 Aug;91 Suppl 2:S31-7. Review.

15.

Regulation of Bim in Health and Disease.

Sionov RV, Vlahopoulos SA, Granot Z.

Oncotarget. 2015 Sep 15;6(27):23058-134. Review.

Items per page

Supplemental Content

Write to the Help Desk